iRemedy and Verséa Holdings Team to Provide COVID-19 Rapid Test Serology Kits to U.S. Medical Providers
NEW YORK, NY & TAMPA , FL– July 8, 2020 – The iRemedy Healthcare Companies, Inc. (“iRemedy” or “the Company”), pioneer of the iRemedy ecommerce platform, and Verséa Holdings, a U.S.-based healthcare company focused on clinical research and novel scientific discoveries and products, today jointly announced the commercial availability of a COVID-19 Rapid Test Serology Kit that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for administration by U.S. healthcare providers in testing patients for coronavirus infection.
One of the key factors in tackling the spread of COVID-19 across the globe is testing. Sean Fetcho, Co-Founder and CEO of Verséa Holdings, noted, “The most important question we face is not how quickly we can ‘reopen the economy.’ The real question is how soon we can establish robust testing in every part of the country to monitor trends to better establish protocols and guidelines.”
The 10-minute Verséa test uses a combination of assays that can help identify positive patients through multivariable analysis of immunoglobin IgG and IgM found in a patient’s whole blood, serum or plasma within 3-5 days after incubation. Offering a stable 24-month shelf life if stored at room temperature or refrigerated (2-30˚ C/36-86˚F), the affordable Verséa test features sensitivity and specificity metrics closely compared to ELISA (enzyme-linked immunoassay) tests: e.g. sensitivity – IgG 97.2%; IgM 87.9% and specificity – IgG 100% and IgM 100%. Verséa is equipped to produce and distribute millions of kits monthly. Here is how it works:
In association with its new partnership with Verséa Holdings, iRemedy will offer the COVID-19 Rapid Response test to healthcare providers on the iRemedy ecommerce platform found at www.iremedy.com.
“Like the virus itself, COVID-19 testing is challenging. For months now, our healthcare provider clients have been requesting testing solutions, so we are confident that Verséa’s test will play an important role in meeting those needs. We are particularly grateful for the long established diagnostic expertise that the Verséa team brings to this process,” added Tony Paquin, Co-Founder and CEO of iRemedy.
About Verséa Holdings Verséa Holdings is a diversified portfolio focused on education, pharmaceuticals, diagnostics and practice solutions. Each division is focused on bringing innovative products and services that are only available through healthcare professionals for their patients. The Verséa management and physician team has 300+ years of pharmaceutical, diagnostic, regulatory, developmental and commercialization expertise with proven success in highly regulated markets. The collective experience of the team spans commercial and clinical operation build-outs, achieving FDA product approvals, successful product launches and lifecycle management. For more information, please visit www.versea.com. www.versea.com.
About The iRemedy Healthcare Companies With 15 years in healthcare supply, iRemedy is a trusted and reliable partner for acquiring medical supplies and Personal Protective Equipment. We service over 5,000 healthcare provider clients nationwide. We guarantee access to verified supplies by sourcing directly from established manufacturers and distributors around the world. Our industry-leading technology and group purchasing power enable transparency and competition, driving consistently low pricing for our customers every day. iRemedy is headquartered in Stuart, Florida and has offices in New York, California and Washington, and distribution centers in Florida and Arizona. For more information, please visit www.iremedy.com.
FOR MORE INFORMATION: Keisha Graham 407-395-4283 | [email protected]